ASLAN Pharma today announced that it will be presenting data from its phase II trial of varlitinib in metastatic HER2-positive breast cancer patients at the ESMO Asia Congress 2017.
Singapore, 8 November 2017 – ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it will be presenting data from its phase 2 trial of varlitinib in metastatic HER2-positive breast cancer patients at the ESMO Asia Congress 2017. The congress will take place from 17-19 November at Suntec Singapore Convention & Exhibition Centre in Singapore.
Varlitinib is a reversible potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs).
Details of the abstract are as follows:
Title: Multicenter Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
Abstract Number: 987
A full-text version of the abstract has been made available online at https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/presentation/list?r=pt~23
